SEC Form 4 · accession 0001209191-17-029869
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Chodakewitz
Officer — EVP GMDA, CMO
Period of report
May 2, 2017
Accepted (ET)
May 4, 2017 · 8:51 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 2, 2017 | M | 8,979 | $91.05 | A | 131,490 | D | |
| Common Stock | May 2, 2017 | S | 8,979 | $121.05 | D | 122,511 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $91.05 | May 2, 2017 | M | 8,979 | D | — | Feb 1, 2026 | Common Stock | 8,979 | 19,756 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Chodakewitz's company approved trading plan under Rule 10b5-1.
- F2The option vests in 16 quarterly installments from 02/02/2016.